References
- Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet [Internet]. 2010;375:1545–1555. Available from https://www.ncbi.nlm.nih.gov/pubmed/20399493
- Collins P, Melero J. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res [Internet]. 2011;162:80–99. Available from: http://www.sciencedirect.com/science/article/pii/S016817021100373X
- Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets [Internet]. 2012;12:92–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22335498
- Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health [Internet]. 2015;5. Available from: http://www.jogh.org/documents/issue201502/jogh-05-020416.pdf
- Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child [Internet]. 1986;140:543–546. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3706232
- Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163:693–698.
- Afonso CL, Amarasinghe GK, Bányai K, et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol [Internet]. 2016;161:2351–2360. Available from: http://link.springer.com/10.1007/s00705-016-2880-1
- Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol [Internet]. 2013;372:3–38. Available from http://link.springer.com/10.1007/978-3-642-38919-1
- Fuentes S, Tran KC, Luthra P, et al. Function of the respiratory syncytial virus small hydrophobic protein. J Virol [Internet]. 2007;81:8361–8366. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.02717-06
- Malhotra R, Ward M, Bright H, et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect. 2003;5:123–133.
- Ouizougun-Oubari M, Pereira N, Tarus B, et al. A druggable pocket at the nucleocapsid/phosphoprotein interaction site of human respiratory syncytial virus. J Virol Methods. 2015;89:11129–11143.
- Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF- B, and proinflammatory cytokines. J Virol [Internet]. 2005;79:5353–5362. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.79.9.5353-5362.2005
- Wright PF, Karron RA, Madhi SA, et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis [Internet]. 2006;193:573–581. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1086/499600
- Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol [Internet]. 1969;89:422–434. Available from: https://academic.oup.com/aje/article-lookup/doi/10.1093/oxfordjournals.aje.a120955
- Kruijsen D, Schijf MA, Lukens MV, et al. Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV. Vaccine [Internet]. 2011;29:2730–2741. Available from https://www.ncbi.nlm.nih.gov/pubmed/21316502
- Piedra PA, Faden HS, Camussi G, et al. Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus. Vaccine. 1989;7:34–38.
- Waris ME, Tsou C, Erdman DD, et al. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol [Internet]. 1996;70:2852–2860. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8627759
- Huang K, Incognito L, Cheng X, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol [Internet]. 2010;84:8132–8140. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.02699-09
- Ambrose CS, Chen X, Kumar VR. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children. Hum Vaccines Immunother. 2014;10:2785–2788.
- Walsh EE. Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med [Internet]. 2017;38:29–36.
- Falsey AR, Walsh EE, Looney RJ, et al. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J Med Virol [Internet]. 1999;59:221–226. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10459160
- Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol. 2004;73:295–299.
- Fuentes S, Coyle EM, Beeler J, et al. Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog. 2016.
- Glezen W, Paredes A, Allison J, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98:708–715.
- Ogilvie M, Vathenen A, Radford M, et al. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol. 1981;7:263–271.
- Chu HY, Steinhoff MC, Magaret A, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis. 2014;210:1582–1589.
- Jans J, Wicht O, Widjaja I, et al. Characteristics of RSV-specific maternal antibodies in plasma of hospitalized, acute RSV patients under three months of age. PLoS One. 2017;12:1–16.
- Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine. 2003;21:3406–3412.
- Jounai N, Yoshioka M, Tozuka M, et al. Age-specific profiles of antibody responses against respiratory syncytial virus infection. EBioMedicine. 2017;16:124–135.
- Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med [Internet]. 2009;15:34–41. Available from: http://www.nature.com/articles/nm.1894
- Ruckwardt TJ, Morabito KM, Graham BS. Determinants of early life immune responses to RSV infection. Curr Opin Virol [Internet]. 2016;16:151–157.
- Sande CJ, Cane PA, Nokes DJ. The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine [Internet]. 2014;32:4726–4729.
- Meurman O, Waris M, Ak H. Immunoglobulin G antibody avidity in patients with respiratory syncytial virus infection. J Clin Microbiol [Internet]. 1992;30:1479–1484. Available from: http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC265314&blobtype=pdf
- Lambert L, Sagfors AM, Openshaw PJM, et al. Immunity to RSV in early-life. Front Immunol [Internet]. 2014;5. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2014.00466/abstract
- Goodwin E, Gilman MSA, Wrapp D, et al. Infants infected with respiratory syncytial virus generate potent neutralizing antibodies that lack somatic hypermutation. Immunity [Internet]. 2018;48:339–349.e5. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1074761318300050
- Palomo C, Mas V, Vázquez M, et al. Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation. Virology [Internet]. 2014;460–461:119–127. Available from:.
- McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (80-.) [Internet]. 2013;340:1113–1117. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.1234914
- McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (80-.) [Internet]. 2013;342:592–598. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.1243283
- Fedechkin SO, George NL, Wolff JT, et al. Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies. Sci Immunol [Internet]. 2018;3:1–8. Available from: http://immunology.sciencemag.org/content/immunology/3/21/eaar3534.full.pdf
- Terrosi C, Di Genova G, Martorelli B, et al. Humoral immunity to respiratory syncytial virus in young and elderly adults. Epidemiol Infect. 2009;137:1684–1686.
- Falsey AR. Respiratory Syncytial virus infection in adults. Crit Care. 2007;1:171–181.
- Malloy AMW, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol [Internet]. 2013;211–231. Available from: http://link.springer.com/10.1007/978-3-642-38919-1_11
- Boukhvalova MS, Yim KC, Kuhn KH, et al. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J Infect Dis [Internet]. 2007;195:511–518. Available from: http://dx.doi.org/10.1086/510628%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=46214393%5Cnhttp://catalogue.leidenuniv.nl/openurl/UBL/UBL_services_page?sid=OVID:Embase&issn=0022-1899&isbn=&volume=195&issue=4&spage=511&d
- Ackerman M, Nimmerjahn F. Antibody Fc: linking adaptive and innate immunity [Internet]. MAbs. 2014. Available from: http://www.tandfonline.com/doi/abs/10.4161/mabs.28617
- Corbeil S, Seguin C, Trudel M. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine [Internet]. 1996;14:521–525. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8782350
- Hiatt A, Bohorova N, Bohorov O, et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci [Internet]. 2014;111:5992–5997. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1402458111
- van Mechelen L, Luytjes W, Cam DH, et al. RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors. Antivir Res [Internet]. 2016;132:1–5. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166354216300390
- Gómez RS, Ramirez BA, Céspedes PF, et al. Contribution of Fc γ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells. Immunology [Internet]. 2016;147:55–72. Available from: http://doi.wiley.com/10.1111/imm.12541
- Janeway CA, Travers P, Walport M, et al. The immune system in health and disease. 5th ed. New York: Garland Science; 2001.
- Cortjens B, Yasuda E, Yu X, et al. Broadly reactive anti-respiratory syncytial virus G antibodies from exposed individuals effectively inhibit infection of primary airway epithelial cells. Perlman S, editor. J. Virol [Internet]. 2017;91:e02357–16. Available from: http://jvi.asm.org/lookup/doi/10.1128/JVI.02357-16
- Habibi MS, Jozwik A, Makris S, et al. Impaired antibody-mediated protection and defective iga b-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015;191:1040–1049.
- Gilman MS, Castellanos C, Chen M, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol [Internet]. 2016;1:eaaj1879–eaaj1879. Available from: http://immunology.sciencemag.org/cgi/doi/10.1126/sciimmunol.aaj1879
- Jacobino SR, Nederend M, Reijneveld JF, et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs [Internet]. 2018;1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29553863
- Widjaja I, Wicht O, Luytjes W, et al. Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV. García-Sastre A, editor. J Virol [Internet]. 2016;90:5965–5977. Available from: http://jvi.asm.org/lookup/doi/10.1128/JVI.00235-16
- Lin Y, Bright AC, Rothermel TA, et al. Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. J Virol [Internet]. 2003;77:3371–3383. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.77.6.3371-3383.2003
- Triantafilou K, Kar S, Vakakis E, et al. Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax. 2013;68:66–75.
- Groothuis JR, Simoes EA, Hemming VG. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics [Internet]. 1995;95:463–467. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7700741
- Oertel MD. RespiGam: an RSV immune globulin. Pediatr Nurs [Internet]. 1996;22:525–528. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9087091
- Wu H, Pfarr DS, Losonsky GA, et al. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol [Internet]. 2008;317:103–123. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17990791
- Gálvez MS, Soto JA, Kalergis AM. New insights contributing to the development of effective vaccines and therapies to reduce the pathology caused by hRSV. Int J Mol Sci. 2017;18(8):1753.
- PATH. Rsv Vaccine and mAb Snapshot. Vaccine Resour Libr. 2018. Available from: https://vaccineresources.org/files/RSV-snapshot-2018July16_High%20Resolution%20V3.pdf
- McLellan JS, Yang Y, Graham BS, et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol [Internet]. 2011;85:7788–7796. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.00555-11
- McLellan JS. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol [Internet]. 2015;11:70–75. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1879625715000334
- Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med [Internet]. 2015;7:309ra162–309ra162. Available from: http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aac4241
- Mousa JJ, Sauer MF, Sevy AM, et al. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proc Natl Acad Sci [Internet]. 2016;113:E6849–E6858. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1609449113
- Domachowske JB, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.. Pediatr Infect Dis J [Internet]. 2018;1. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29373476
- Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem [Internet]. 2006;281:23514–23524. Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.M604292200
- Detalle L, Stohr T, Palomo C, et al. Generation and Characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother [Internet]. 2016;60:6–13. Available from: http://aac.asm.org/lookup/doi/10.1128/AAC.01802-15
- Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: immunoprophylaxis. Adv Ther. 2011;28:110–125.
- Murphy BR, Prince GA, Walsh EE. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986;24:197–202.
- Killikelly AM, Kanekiyo M, Graham BS. Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep [Internet]. 2016;6:1–7.
- Jaberolansar N, Chappell KJ, Watterson D, et al. Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein. Sci Rep [Internet]. 2017;7:1–11.
- August A, Glenn GM, Kpamegan E, et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine [Internet]. 2017;35:3749–3759. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X17306813
- Tripp RA, Power UF, Openshaw PJM, et al. Respiratory syncytial virus: targeting the G protein provides a new approach for an old problem. J Virol [Internet]. 2017;92:e01302–17. Available from: http://jvi.asm.org/lookup/doi/10.1128/JVI.01302-17
- Bukreyev A, Yang L, Fricke J, et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes ᰔ. J Virol. 2008;82:12191–12204.
- Bukreyev A, Yang L, Collins PL. The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement. J Virol. 2012;86:10880–10884.
- Levine S, Klaiber-Franco R, Paradiso PR. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol [Internet]. 1987;68:2521–2524. Available from: http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-68-9-2521
- Johnson PR, Spriggs MK, Olmsted RA, et al. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci [Internet]. 1987;84:5625–5629. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.84.16.5625
- Johnson SM, McNally BA, Ioannidis I, et al. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog. 2015;11:1–16.
- Il JK, Piepenhagen PA, Kishko M, et al. CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner. PLoS One. 2015;10:1–13.
- Boyoglu-Barnum S, Gaston K, Todd SO, et al. A respiratory syncytial virus (RSV) anti-G protein F(ab’)2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol [Internet]. 2013;87:10955–10967. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3807296&tool=pmcentrez&rendertype=abstract
- Boyoglu-Barnum S, Todd SO, Chirkova T, et al. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology [Internet]. 2015;483:117–125. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0042682215000811
- Caidi H, Harcourt JL, Tripp RA, et al. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c Mice. PLoS One. 2012;7:1–9.
- Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis [Internet]. 2009;200:439–447. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1086/600108
- Lee H-J, Lee J-Y, Park M-H, et al. Monoclonal antibody against G glycoprotein increases respiratory syncytial virus clearance in vivo and prevents vaccine-enhanced diseases. Varga SM, editor. PLoS One [Internet]. 2017;12:e0169139. Available from: http://dx.plos.org/10.1371/journal.pone.0169139
- Caidi H, Miao C, Thornburg NJ, et al. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antivir Res [Internet]. 2018;154:149–157. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0166354217307660
- Grad YH, Newman R, Zody M, et al. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol [Internet]. 2014;88:7286–7293. Available from: http://jvi.asm.org/cgi/doi/10.1128/JVI.00038-14
- Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Exp Rev Respir Med [Internet]. 2017;11:609–615.
- Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol. 2001;2:732–738.
- Haynes LM, Jones LP, Barskey A, et al. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol [Internet]. 2003;77:9831–9844. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12941892
- Arnold R, König B, Werchau H, et al. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology. 2004;330:384–397.
- Harcourt J, Alvarez R, Jones LP, et al. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol [Internet]. 2006;176:1600–1608. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16424189
- Chirkova T, Lin S, Oomens AGP, et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol [Internet]. 2015;96:2543–2556. Available from: http://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.000218
- Han J, Takeda K, Wang M, et al. Effects of anti-G and anti-F antibodies on airway function after respiratory syncytial virus infection. Am J Respir Cell Mol Biol. 2014;51:143–154.
- Kauvar LM, Harcourt JL, Haynes LM, et al. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy [Internet]. 2010;2:655–661. Available from: http://www.futuremedicine.com/doi/10.2217/imt.10.53
- Olmsted RA, Collins PL. The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species. J Virol [Internet]. 1989;63:2019–2029. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=250617&tool=pmcentrez&rendertype=abstract
- Collins PL, Olmsted RA, Johnson PR. The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B. J Gen Virol. 1990;71:1571–1576.
- Schepens B, Sedeyn K, Vande GL, et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. 2014;6:1436–1454.
- Gonzalez PA, Prado CE, Leiva ED, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci [Internet]. 2008;105:14999–15004. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.0802555105
- Cespedes PF, Bueno SM, Ramirez BA, et al. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. Proc Natl Acad Sci [Internet]. 2014;111:E3214–E3223. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1400760111
- Bueno SM, González PA, Cautivo KM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A [Internet]. 2008;105:20822–20827. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2634951&tool=pmcentrez&rendertype=abstract%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/19075247%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2634951
- Céspedes PF, Rey-Jurado E, Espinoza JA, et al. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice. Vaccine. 2017;35:757–766.
- Cautivo KM, Bueno SM, Cortes CM, et al. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette–Guerin promotes virus clearance and protects from infection. J Immunol [Internet]. 2010;185:7633–7645. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.0903452
- Rey-Jurado E, Soto J, Gálvez N, et al. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human respiratory syncytial virus. Hum Vaccin Immunother [Internet]. 2017;13:2092–2097. Available from: https://www.tandfonline.com/doi/full/10.1080/21645515.2017.1334026
- Espinoza JA, Bohmwald K, Cespedes PF, et al. Impaired learning resulting from respiratory syncytial virus infection. Proc Natl Acad Sci [Internet]. 2013;110:9112–9117. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1217508110
- Gómez RS, Mora JE, Cortés CM, et al. Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies. J Med Virol [Internet]. 2014;86:1256–1266. Available from: http://doi.wiley.com/10.1002/jmv.23807
- Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol [Internet]. 2010;10:301–316. Available from: http://www.nature.com/articles/nri2761
- Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc–fcγR interactions in IgG-mediated microbial neutralization. J Exp Med [Internet]. 2015;212:1361–1369. Available from: http://www.jem.org/lookup/doi/10.1084/jem.20151267
- Sparrow E, Friede M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Health Organ. 2017;95:235–237.
- Mullard A. FDA approves antitoxin antibody. Nat Rev Drug Discov [Internet]. 2016;15:811. Available from: http://www.nature.com/doifinder/10.1038/nrd.2016.257
- Rey-Jurado E, Tapia F, Muñoz-Durango N, et al. Assessing the importance of domestic vaccine manufacturing centers: an overview of immunization programs, vaccine manufacture, and distribution. Front Immunol [Internet]. 2018;9. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2018.00026/full
- Fenton C, Scott LJ, Plosker GL. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs [Internet]. 2004;6:177–197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15170364
- The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics [Internet]. 1998;102:531–537. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9724660